Daiichi-Sankyo Partnering Day

Daiichi-Sankyo is a global pharmaceutical company with corporate origins in Japan. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.

Through the outstanding knowledge and commitment of over 15,000 employees worldwide, we create innovative medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

For more information about us, please visit at  www.daiichisankyo.com

Oncology (biologics) – Novel targets/biologics associated with

1. tumor immune suppression, immune escape or immune checkpoints
2. cancer stem cells and/or chemo-resistant cells
3. tumor microenvironment such as solid tumor stroma.

Oncology (small molecules) – Novel targets/small molecules associated with

1. Epigenetics
2. Cancer metabolism
3. Cancer microenvironment
4. Growth/survival signals
5. Cancer stemness, differentiation
6. Immuno-oncology

Pain – Compounds associated with 

1. μ-opioid receptor signaling
2. NGF signal inhibition (except anti-NGF antibodies and TrkA kinase inhibitors)

Target molecules associated with Brain function/network reinforcing chronic pain

Sensory – Target molecules associated with

1. Vision loss from retinal degeneration
2. Sensorineural hearing loss
3. Endolymphatic hydrops (Ménière’s disease)

which especially induce regeneration of neuronal and sensory cells, alter protein degradation/trafficking in neurons, control volume and composition of endolymph.

CVM – Novel target molecules associated with

1. Acute & chronic heart failure and arrhythmia
2. Acute & chronic kidney diseases
3. Vascular dysfunction associated diseases
4. Fibrotic diseases (Pulmonary fibrosis, Hepatic, Gastrointestinal)
5. Obesity
6. Other endo-organ diseases (Respiratory, Hepatic, GI, etc.)

Monogenic / Rare Diseases – Innovative therapeutics for genetically defined diseases with high unmet medical needs (severe/progressive/high lethality).

Nucleic acid therapeutics – Novel DDS technology for nucleic acid therapeutics (Antisense oligonucleotides/ siRNA/ mRNA).

Gene therapy – Novel technology for gene therapy like viral vectors or DDS, which can overcome existing problems of current technology.

Cell therapy – Research on novel somatic stem/progenitor cells (SSCs/PCs) that have therapeutic potentials for serious diseases with very limited treatment options.

Confirmed Daiichi Sankyo Participants